ValuEngine upgraded shares of Recro Pharma (NASDAQ:REPH) from a sell rating to a hold rating in a research report report published on Thursday morning.
REPH has been the topic of a number of other reports. Oppenheimer restated a buy rating on shares of Recro Pharma in a report on Thursday, April 5th. Zacks Investment Research downgraded shares of Recro Pharma from a hold rating to a sell rating in a report on Tuesday, May 15th. Piper Jaffray Companies cut their price target on shares of Recro Pharma from $17.00 to $9.00 and set an overweight rating on the stock in a report on Thursday, May 24th. BidaskClub upgraded shares of Recro Pharma from a hold rating to a buy rating in a report on Thursday, May 24th. Finally, Janney Montgomery Scott cut their price target on shares of Recro Pharma from $21.00 to $11.00 and set a fair value rating on the stock in a report on Thursday, May 24th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock presently has a consensus rating of Buy and an average target price of $12.63.
Shares of Recro Pharma traded up $0.22, reaching $5.02, during trading hours on Thursday, MarketBeat reports. The company’s stock had a trading volume of 224,500 shares, compared to its average volume of 314,090. Recro Pharma has a one year low of $4.78 and a one year high of $13.05. The company has a quick ratio of 1.55, a current ratio of 1.78 and a debt-to-equity ratio of 2.20. The company has a market cap of $102.74 million, a PE ratio of -2.52 and a beta of -0.97.
Recro Pharma (NASDAQ:REPH) last posted its earnings results on Wednesday, May 9th. The specialty pharmaceutical company reported ($0.65) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.03. Recro Pharma had a negative net margin of 74.85% and a negative return on equity of 105.78%. The firm had revenue of $19.54 million for the quarter, compared to the consensus estimate of $17.32 million. sell-side analysts expect that Recro Pharma will post -3.1 earnings per share for the current fiscal year.
In related news, major shareholder Healthcare Master Fun Broadfin sold 188,000 shares of the company’s stock in a transaction dated Thursday, May 24th. The shares were sold at an average price of $5.81, for a total transaction of $1,092,280.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 21.60% of the company’s stock.
A number of large investors have recently modified their holdings of the stock. JT Stratford LLC grew its holdings in Recro Pharma by 7.8% during the 4th quarter. JT Stratford LLC now owns 112,265 shares of the specialty pharmaceutical company’s stock valued at $1,038,000 after purchasing an additional 8,120 shares during the last quarter. Jump Trading LLC bought a new position in Recro Pharma in the 1st quarter worth about $124,000. Citadel Advisors LLC bought a new position in Recro Pharma in the 1st quarter worth about $126,000. Cubist Systematic Strategies LLC bought a new position in Recro Pharma in the 1st quarter worth about $139,000. Finally, BlackRock Inc. grew its stake in Recro Pharma by 1.4% in the 4th quarter. BlackRock Inc. now owns 1,011,855 shares of the specialty pharmaceutical company’s stock worth $9,359,000 after acquiring an additional 13,799 shares in the last quarter. Institutional investors own 56.15% of the company’s stock.
Recro Pharma Company Profile
Recro Pharma, Inc, a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.